1
|
Boerth JA, Chinn AJ, Schimpl M, Bommakanti G, Chan C, Code EL, Giblin KA, Gohlke A, Hansel CS, Jin M, Kavanagh SL, Lamb ML, Lane JS, Larner CJB, Mfuh AM, Moore RK, Puri T, Quinn TR, Ye M, Robbins KJ, Gancedo-Rodrigo M, Tang H, Walsh J, Ware J, Wrigley GL, Reddy IK, Zhang Y, Grimster NP. Discovery of a Novel Benzodiazepine Series of Cbl-b Inhibitors for the Enhancement of Antitumor Immunity. ACS Med Chem Lett 2023; 14:1848-1856. [PMID: 38116444 PMCID: PMC10726479 DOI: 10.1021/acsmedchemlett.3c00439] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2023] [Revised: 11/09/2023] [Accepted: 11/10/2023] [Indexed: 12/21/2023] Open
Abstract
Casitas B-lineage lymphoma proto-oncogene-b (Cbl-b) is a RING finger E3 ligase that is responsible for repressing T-cell, natural killer (NK) cell, and B-cell activation. The robust antitumor activity observed in Cbl-b deficient mice arising from elevated T-cell and NK-cell activity justified our discovery effort toward Cbl-b inhibitors that might show therapeutic promise in immuno-oncology, where activation of the immune system can drive the recognition and killing of cancer cells. We undertook a high-throughput screening campaign followed by structure-enabled optimization to develop a novel benzodiazepine series of potent Cbl-b inhibitors. This series displayed nanomolar levels of biochemical potency, as well as potent T-cell activation. The functional activity of this class of Cbl-b inhibitors was further corroborated with ubiquitin-based cellular assays.
Collapse
Affiliation(s)
- Jeffrey A. Boerth
- Medicinal
Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Alex J. Chinn
- Medicinal
Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Marianne Schimpl
- Discovery
Sciences, R&D, The Discovery Centre, AstraZeneca, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom
| | - Gayathri Bommakanti
- Bioscience,
Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Christina Chan
- DMPK,
Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom
| | - Erin L. Code
- Discovery
Sciences, R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Kathryn A. Giblin
- Medicinal
Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge
Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom
| | - Andrea Gohlke
- Discovery
Sciences, R&D, The Discovery Centre, AstraZeneca, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom
| | - Catherine S. Hansel
- Discovery
Sciences, R&D, The Discovery Centre, AstraZeneca, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom
| | - Meizhong Jin
- Medicinal
Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Stefan L. Kavanagh
- Clinical
Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom
| | - Michelle L. Lamb
- Medicinal
Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Jordan S. Lane
- Discovery
Sciences, R&D, The Discovery Centre, AstraZeneca, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom
| | - Carrie J. B. Larner
- Clinical
Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom
| | - Adelphe M. Mfuh
- Medicinal
Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Rachel K. Moore
- High
Throughput Screening, Hit Discovery, Discovery Sciences, R&D BioPharmaceuticals, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, United Kingdom
| | - Taranee Puri
- Medicinal
Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Taylor R. Quinn
- Medicinal
Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Minwei Ye
- Bioscience,
Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Kevin J. Robbins
- Medicinal
Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Miguel Gancedo-Rodrigo
- Discovery
Sciences, R&D, The Discovery Centre, AstraZeneca, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom
| | - Haoran Tang
- Discovery
Sciences, R&D, The Discovery Centre, AstraZeneca, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom
| | - Jarrod Walsh
- High
Throughput Screening, Hit Discovery, Discovery Sciences, R&D BioPharmaceuticals, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, United Kingdom
| | - Jamie Ware
- Discovery
Sciences, R&D, The Discovery Centre, AstraZeneca, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom
| | - Gail L. Wrigley
- Medicinal
Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge
Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom
| | - Iswarya Karapa Reddy
- Bioscience,
Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Yun Zhang
- Medicinal
Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Neil P. Grimster
- Medicinal
Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| |
Collapse
|
2
|
Hansel CS, Lanne A, Rowlands H, Shaw J, Collier MJ, Plant H. High-throughput differential scanning fluorimetry (DSF) and cellular thermal shift assays (CETSA): Shifting from manual to automated screening. SLAS Technol 2023; 28:411-415. [PMID: 37598756 DOI: 10.1016/j.slast.2023.08.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2023] [Revised: 08/09/2023] [Accepted: 08/16/2023] [Indexed: 08/22/2023]
Abstract
Biophysical affinity screening is increasingly being adopted as a high-throughput hit finding technique in drug discovery. Automation is highly beneficial to high-throughput screening (HTS) since a large number of compounds need to be reproducibly tested against a biological target. Herein, we describe how we have automated two biophysical affinity screening methods that rely on a thermal shift in protein melting temperature upon small molecule binding: differential scanning fluorimetry (DSF) and the cellular thermal shift assay (CETSA).
Collapse
Affiliation(s)
- Catherine S Hansel
- High-throughput Screening, Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Alderley Park, UK.
| | - Alice Lanne
- High-throughput Screening, Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Alderley Park, UK
| | - Hannah Rowlands
- High-throughput Screening, Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Alderley Park, UK
| | - Joseph Shaw
- Assay Development, Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK
| | - Matthew J Collier
- High-throughput Screening, Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Alderley Park, UK
| | - Helen Plant
- High-throughput Screening, Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Alderley Park, UK
| |
Collapse
|
3
|
Speidel AT, Chivers PRA, Wood CS, Roberts DA, Correia IP, Caravaca AS, Chan YKV, Hansel CS, Heimgärtner J, Müller E, Ziesmer J, Sotiriou GA, Olofsson PS, Stevens MM. Tailored Biocompatible Polyurethane-Poly(ethylene glycol) Hydrogels as a Versatile Nonfouling Biomaterial. Adv Healthc Mater 2022; 11:e2201378. [PMID: 35981326 PMCID: PMC7615486 DOI: 10.1002/adhm.202201378] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2022] [Revised: 07/28/2022] [Indexed: 01/28/2023]
Abstract
Polyurethane-based hydrogels are relatively inexpensive and mechanically robust biomaterials with ideal properties for various applications, including drug delivery, prosthetics, implant coatings, soft robotics, and tissue engineering. In this report, a simple method is presented for synthesizing and casting biocompatible polyurethane-poly(ethylene glycol) (PU-PEG) hydrogels with tunable mechanical properties, nonfouling characteristics, and sustained tolerability as an implantable material or coating. The hydrogels are synthesized via a simple one-pot method using commercially available precursors and low toxicity solvents and reagents, yielding a consistent and biocompatible gel platform primed for long-term biomaterial applications. The mechanical and physical properties of the gels are easily controlled by varying the curing concentration, producing networks with complex shear moduli of 0.82-190 kPa, similar to a range of human soft tissues. When evaluated against a mechanically matched poly(dimethylsiloxane) (PDMS) formulation, the PU-PEG hydrogels demonstrated favorable nonfouling characteristics, including comparable adsorption of plasma proteins (albumin and fibrinogen) and significantly reduced cellular adhesion. Moreover, preliminary murine implant studies reveal a mild foreign body response after 41 days. Due to the tunable mechanical properties, excellent biocompatibility, and sustained in vivo tolerability of these hydrogels, it is proposed that this method offers a simplified platform for fabricating soft PU-based biomaterials for a variety of applications.
Collapse
Affiliation(s)
- Alessondra T Speidel
- Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, 171 77, Sweden
| | - Phillip R A Chivers
- Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, 171 77, Sweden
| | - Christopher S Wood
- Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, 171 77, Sweden
| | - Derrick A Roberts
- Key Centre for Polymers and Colloids, School of Chemistry, The University of Sydney, Sydney, NSW, 2006, Australia
| | - Inês P Correia
- Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, 171 77, Sweden
| | - April S Caravaca
- Laboratory of Immunobiology, Stockholm Center for Bioelectronic Medicine, Department of Medicine, Solna, Karolinska Institutet, Stockholm, 171 77, Sweden
| | - Yu Kiu Victor Chan
- Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, 171 77, Sweden
| | - Catherine S Hansel
- Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, 171 77, Sweden
| | - Johannes Heimgärtner
- Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, 171 77, Sweden
| | - Eliane Müller
- Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, 171 77, Sweden
| | - Jill Ziesmer
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, 171 77, Sweden
| | - Georgios A Sotiriou
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, 171 77, Sweden
| | - Peder S Olofsson
- Laboratory of Immunobiology, Stockholm Center for Bioelectronic Medicine, Department of Medicine, Solna, Karolinska Institutet, Stockholm, 171 77, Sweden
- Center for Biomedical Science and Bioelectronic Medicine, The Feinstein Institute for Medical Research, Manhasset, NY, 11030, USA
| | - Molly M Stevens
- Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, 171 77, Sweden
- Department of Materials, Department of Bioengineering, and Institute for Biomedical Engineering, Imperial College London, London, SW7 2AZ, UK
| |
Collapse
|
4
|
Artzy-Schnirman A, Abu-Shah E, Chandrawati R, Altman E, Yusuf N, Wang ST, Ramos J, Hansel CS, Haus-Cohen M, Dahan R, Arif S, Dustin ML, Peakman M, Reiter Y, Stevens MM. Artificial Antigen Presenting Cells for Detection and Desensitization of Autoreactive T cells Associated with Type 1 Diabetes. Nano Lett 2022; 22:4376-4382. [PMID: 35616515 PMCID: PMC9185737 DOI: 10.1021/acs.nanolett.2c00819] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 02/28/2022] [Revised: 05/11/2022] [Indexed: 06/15/2023]
Abstract
Autoimmune diseases and in particular type 1 diabetes rely heavily on treatments that target the symptoms rather than prevent the underlying disease. One of the barriers to better therapeutic strategies is the inability to detect and efficiently target rare autoreactive T-cell populations that are major drivers of these conditions. Here, we develop a unique artificial antigen-presenting cell (aAPC) system from biocompatible polymer particles that allows specific encapsulation of bioactive ingredients. Using our aAPC, we demonstrate that we are able to detect rare autoreactive CD4 populations in human patients, and using mouse models, we demonstrate that our particles are able to induce desensitization in the autoreactive population. This system provides a promising tool that can be used in the prevention of autoimmunity before disease onset.
Collapse
Affiliation(s)
- Arbel Artzy-Schnirman
- Department
of Materials, Department of Bioengineering and Institute for Biomedical
Engineering, Imperial College London, Prince Consort Road, London SW7 2AZ, U.K.
| | - Enas Abu-Shah
- Kennedy
Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology
and Musculoskeletal Sciences, University
of Oxford, Oxford OX3 7FY, U.K.
- Sir
William Dunn School of Pathology, University
of Oxford, Oxford OX1 3RE, U.K.
| | - Rona Chandrawati
- Department
of Materials, Department of Bioengineering and Institute for Biomedical
Engineering, Imperial College London, Prince Consort Road, London SW7 2AZ, U.K.
| | - Efrat Altman
- Laboratory
of Molecular Immunology, Faculty of Biology and Technion Integrated
Cancer Center, Technion-Israel Institute
of Technology, Haifa 3200003, Israel
| | - Norkhairin Yusuf
- Department
of Immunobiology, Guy’s, King’s
& St Thomas’ School of Medicine, second Floor, New Guy’s
House, Guy’s Hospital, London SE1 9RT, U.K.
| | - Shih-Ting Wang
- Department
of Materials, Department of Bioengineering and Institute for Biomedical
Engineering, Imperial College London, Prince Consort Road, London SW7 2AZ, U.K.
| | - Jose Ramos
- Department
of Materials, Department of Bioengineering and Institute for Biomedical
Engineering, Imperial College London, Prince Consort Road, London SW7 2AZ, U.K.
| | - Catherine S. Hansel
- Department
of Materials, Department of Bioengineering and Institute for Biomedical
Engineering, Imperial College London, Prince Consort Road, London SW7 2AZ, U.K.
| | - Maya Haus-Cohen
- Laboratory
of Molecular Immunology, Faculty of Biology and Technion Integrated
Cancer Center, Technion-Israel Institute
of Technology, Haifa 3200003, Israel
| | - Rony Dahan
- Department
of Systems Immunology, Weizmann Institute
of Science, Rehovot 761001, Israel
| | - Sefina Arif
- Department
of Immunobiology, Guy’s, King’s
& St Thomas’ School of Medicine, second Floor, New Guy’s
House, Guy’s Hospital, London SE1 9RT, U.K.
| | - Michael L. Dustin
- Kennedy
Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology
and Musculoskeletal Sciences, University
of Oxford, Oxford OX3 7FY, U.K.
| | - Mark Peakman
- Department
of Immunobiology, Guy’s, King’s
& St Thomas’ School of Medicine, second Floor, New Guy’s
House, Guy’s Hospital, London SE1 9RT, U.K.
| | - Yoram Reiter
- Laboratory
of Molecular Immunology, Faculty of Biology and Technion Integrated
Cancer Center, Technion-Israel Institute
of Technology, Haifa 3200003, Israel
| | - Molly M. Stevens
- Department
of Materials, Department of Bioengineering and Institute for Biomedical
Engineering, Imperial College London, Prince Consort Road, London SW7 2AZ, U.K.
| |
Collapse
|
5
|
Hansel CS, Holme MN, Gopal S, Stevens MM. Advances in high-resolution microscopy for the study of intracellular interactions with biomaterials. Biomaterials 2020; 226:119406. [DOI: 10.1016/j.biomaterials.2019.119406] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2019] [Revised: 07/16/2019] [Accepted: 08/01/2019] [Indexed: 12/15/2022]
|
6
|
Kim E, Zwi-Dantsis L, Reznikov N, Hansel CS, Agarwal S, Stevens MM. One-Pot Synthesis of Multiple Protein-Encapsulated DNA Flowers and Their Application in Intracellular Protein Delivery. Adv Mater 2017; 29:10.1002/adma.201701086. [PMID: 28474844 PMCID: PMC5516917 DOI: 10.1002/adma.201701086] [Citation(s) in RCA: 91] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/23/2017] [Revised: 03/30/2017] [Indexed: 05/19/2023]
Abstract
Inspired by biological systems, many biomimetic methods suggest fabrication of functional materials with unique physicochemical properties. Such methods frequently generate organic-inorganic composites that feature highly ordered hierarchical structures with intriguing properties, distinct from their individual components. A striking example is that of DNA-inorganic hybrid micro/nanostructures, fabricated by the rolling circle technique. Here, a novel concept for the encapsulation of bioactive proteins in DNA flowers (DNF) while maintaining the activity of protein payloads is reported. A wide range of proteins, including enzymes, can be simultaneously associated with the growing DNA strands and Mg2 PPi crystals during the rolling circle process, ultimately leading to the direct immobilization of proteins into DNF. The unique porous structure of this construct, along with the abundance of Mg ions and DNA molecules present, provides many interaction sites for proteins, enabling high loading efficiency and enhanced stability. Further, as a proof of concept, it is demonstrated that the DNF can deliver payloads of cytotoxic protein (i.e., RNase A) to the cells without a loss in its biological function and structural integrity, resulting in highly increased cell death compared to the free protein.
Collapse
Affiliation(s)
- Eunjung Kim
- Department of Materials, Department of Bioengineering and Institute for
Biomedical Engineering, Imperial College London, London, SW7 2AZ, United
Kingdom
| | - Limor Zwi-Dantsis
- Department of Materials, Department of Bioengineering and Institute for
Biomedical Engineering, Imperial College London, London, SW7 2AZ, United
Kingdom
| | - Natalie Reznikov
- Department of Materials, Department of Bioengineering and Institute for
Biomedical Engineering, Imperial College London, London, SW7 2AZ, United
Kingdom
| | - Catherine S. Hansel
- Department of Materials, Department of Bioengineering and Institute for
Biomedical Engineering, Imperial College London, London, SW7 2AZ, United
Kingdom
| | - Shweta Agarwal
- Department of Materials, Department of Bioengineering and Institute for
Biomedical Engineering, Imperial College London, London, SW7 2AZ, United
Kingdom
| | - Molly M. Stevens
- Department of Materials, Department of Bioengineering and Institute for
Biomedical Engineering, Imperial College London, London, SW7 2AZ, United
Kingdom
| |
Collapse
|
7
|
Horejs CM, St-Pierre JP, Ojala JRM, Steele JAM, da Silva PB, Rynne-Vidal A, Maynard SA, Hansel CS, Rodríguez-Fernández C, Mazo MM, You AYF, Wang AJ, von Erlach T, Tryggvason K, López-Cabrera M, Stevens MM. Preventing tissue fibrosis by local biomaterials interfacing of specific cryptic extracellular matrix information. Nat Commun 2017; 8:15509. [PMID: 28593951 PMCID: PMC5472175 DOI: 10.1038/ncomms15509] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2016] [Accepted: 04/04/2017] [Indexed: 12/22/2022] Open
Abstract
Matrix metalloproteinases (MMPs) contribute to the breakdown of tissue structures such as the basement membrane, promoting tissue fibrosis. Here we developed an electrospun membrane biofunctionalized with a fragment of the laminin β1-chain to modulate the expression of MMP2 in this context. We demonstrate that interfacing of the β1-fragment with the mesothelium of the peritoneal membrane via a biomaterial abrogates the release of active MMP2 in response to transforming growth factor β1 and rescues tissue integrity ex vivo and in vivo in a mouse model of peritoneal fibrosis. Importantly, our data demonstrate that the membrane inhibits MMP2 expression. Changes in the expression of epithelial-to-mesenchymal transition (EMT)-related molecules further point towards a contribution of the modulation of EMT. Biomaterial-based presentation of regulatory basement membrane signals directly addresses limitations of current therapeutic approaches by enabling a localized and specific method to counteract MMP2 release applicable to a broad range of therapeutic targets.
Collapse
Affiliation(s)
- Christine-Maria Horejs
- Department of Materials, Imperial College London, Exhibition Road, London SW7 2AZ, UK.,Department of Bioengineering, Imperial College London, Exhibition Road, London SW7 2AZ, UK.,Institute of Biomedical Engineering, Imperial College London, Exhibition Road, London SW7 2AZ, UK.,Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Scheeles väg 2, Stockholm 17177, Sweden
| | - Jean-Philippe St-Pierre
- Department of Materials, Imperial College London, Exhibition Road, London SW7 2AZ, UK.,Department of Bioengineering, Imperial College London, Exhibition Road, London SW7 2AZ, UK.,Institute of Biomedical Engineering, Imperial College London, Exhibition Road, London SW7 2AZ, UK
| | - Juha R M Ojala
- Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Scheeles väg 2, Stockholm 17177, Sweden
| | - Joseph A M Steele
- Department of Materials, Imperial College London, Exhibition Road, London SW7 2AZ, UK.,Department of Bioengineering, Imperial College London, Exhibition Road, London SW7 2AZ, UK.,Institute of Biomedical Engineering, Imperial College London, Exhibition Road, London SW7 2AZ, UK.,Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Scheeles väg 2, Stockholm 17177, Sweden
| | - Patricia Barros da Silva
- Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Scheeles väg 2, Stockholm 17177, Sweden
| | - Angela Rynne-Vidal
- Centro de Biología Molecular Severo Ochoa, CSIC, Universidad Autónoma de Madrid, Campus de Cantoblanco, 28049 Madrid, Spain
| | - Stephanie A Maynard
- Department of Materials, Imperial College London, Exhibition Road, London SW7 2AZ, UK.,Department of Bioengineering, Imperial College London, Exhibition Road, London SW7 2AZ, UK.,Institute of Biomedical Engineering, Imperial College London, Exhibition Road, London SW7 2AZ, UK
| | - Catherine S Hansel
- Department of Materials, Imperial College London, Exhibition Road, London SW7 2AZ, UK.,Department of Bioengineering, Imperial College London, Exhibition Road, London SW7 2AZ, UK.,Institute of Biomedical Engineering, Imperial College London, Exhibition Road, London SW7 2AZ, UK.,Department of Chemistry, Imperial College London, Imperial College Road, London SW7 2AZ, UK
| | - Clara Rodríguez-Fernández
- Department of Materials, Imperial College London, Exhibition Road, London SW7 2AZ, UK.,Department of Bioengineering, Imperial College London, Exhibition Road, London SW7 2AZ, UK.,Institute of Biomedical Engineering, Imperial College London, Exhibition Road, London SW7 2AZ, UK
| | - Manuel M Mazo
- Department of Materials, Imperial College London, Exhibition Road, London SW7 2AZ, UK.,Department of Bioengineering, Imperial College London, Exhibition Road, London SW7 2AZ, UK.,Institute of Biomedical Engineering, Imperial College London, Exhibition Road, London SW7 2AZ, UK
| | - Amanda Y F You
- Department of Materials, Imperial College London, Exhibition Road, London SW7 2AZ, UK.,Department of Bioengineering, Imperial College London, Exhibition Road, London SW7 2AZ, UK.,Institute of Biomedical Engineering, Imperial College London, Exhibition Road, London SW7 2AZ, UK
| | - Alex J Wang
- Department of Materials, Imperial College London, Exhibition Road, London SW7 2AZ, UK.,Department of Bioengineering, Imperial College London, Exhibition Road, London SW7 2AZ, UK.,Institute of Biomedical Engineering, Imperial College London, Exhibition Road, London SW7 2AZ, UK
| | - Thomas von Erlach
- Department of Materials, Imperial College London, Exhibition Road, London SW7 2AZ, UK.,Department of Bioengineering, Imperial College London, Exhibition Road, London SW7 2AZ, UK.,Institute of Biomedical Engineering, Imperial College London, Exhibition Road, London SW7 2AZ, UK
| | - Karl Tryggvason
- Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Scheeles väg 2, Stockholm 17177, Sweden.,Cardiovascular and Metabolic Disorders Program, Duke-NUS, 8 College Road, Singapore 169857, Singapore
| | - Manuel López-Cabrera
- Centro de Biología Molecular Severo Ochoa, CSIC, Universidad Autónoma de Madrid, Campus de Cantoblanco, 28049 Madrid, Spain
| | - Molly M Stevens
- Department of Materials, Imperial College London, Exhibition Road, London SW7 2AZ, UK.,Department of Bioengineering, Imperial College London, Exhibition Road, London SW7 2AZ, UK.,Institute of Biomedical Engineering, Imperial College London, Exhibition Road, London SW7 2AZ, UK.,Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Scheeles väg 2, Stockholm 17177, Sweden
| |
Collapse
|
8
|
Pashuck ET, Duchet BJR, Hansel CS, Maynard SA, Chow LW, Stevens MM. Controlled Sub-Nanometer Epitope Spacing in a Three-Dimensional Self-Assembled Peptide Hydrogel. ACS Nano 2016; 10:11096-11104. [PMID: 28024362 DOI: 10.1021/acsnano.6b05975] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Cells in the body use a variety of mechanisms to ensure the specificity and efficacy of signal transduction. One way that this is achieved is through tight spatial control over the position of different proteins, signaling sequences, and biomolecules within and around cells. For instance, the extracellular matrix protein fibronectin presents RGDS and PHSRN sequences that synergistically bind the α5β1 integrin when separated by 3.2 nm but are unable to bind when this distance is >5.5 nm.1 Building biomaterials to controllably space different epitopes with subnanometer accuracy in a three-dimensional (3D) hydrogel is challenging. Here, we synthesized peptides that self-assemble into nanofiber hydrogels utilizing the β-sheet motif, which has a known regular spacing along the peptide backbone. By modifying specific locations along the peptide, we are able to controllably space different epitopes with subnanometer accuracy at distances from 0.7 nm to over 6 nm, which is within the size range of many protein clusters. Endothelial cells encapsulated within hydrogels displaying RGDS and PHSRN in the native 3.2 nm spacing showed a significant upregulation in the expression of the alpha 5 integrin subunit compared to those in hydrogels with a 6.2 nm spacing, demonstrating the physiological relevance of the spacing. Furthermore, after 24 h the cells in hydrogels with the 3.2 nm spacing appeared to be more spread with increased staining for the α5β1 integrin. This self-assembling peptide system can controllably space multiple epitopes with subnanometer accuracy, demonstrating an exciting platform to study the effects of ligand density and location on cells within a synthetic 3D environment.
Collapse
Affiliation(s)
- E Thomas Pashuck
- Department of Materials, ‡Department of Bioengineering, §Institute of Biomedical Engineering, and ⊥Department of Chemistry, Imperial College London , London SW7 2AZ, United Kingdom
| | - Benoît J R Duchet
- Department of Materials, ‡Department of Bioengineering, §Institute of Biomedical Engineering, and ⊥Department of Chemistry, Imperial College London , London SW7 2AZ, United Kingdom
| | - Catherine S Hansel
- Department of Materials, ‡Department of Bioengineering, §Institute of Biomedical Engineering, and ⊥Department of Chemistry, Imperial College London , London SW7 2AZ, United Kingdom
| | - Stephanie A Maynard
- Department of Materials, ‡Department of Bioengineering, §Institute of Biomedical Engineering, and ⊥Department of Chemistry, Imperial College London , London SW7 2AZ, United Kingdom
| | - Lesley W Chow
- Department of Materials, ‡Department of Bioengineering, §Institute of Biomedical Engineering, and ⊥Department of Chemistry, Imperial College London , London SW7 2AZ, United Kingdom
| | - Molly M Stevens
- Department of Materials, ‡Department of Bioengineering, §Institute of Biomedical Engineering, and ⊥Department of Chemistry, Imperial College London , London SW7 2AZ, United Kingdom
| |
Collapse
|